Leap Therapeutics Inc LPTX

NAS: LPTX | ISIN: US52187K1016   8/05/2024
2,990 USD (-2,61%)
(-2,61%)   8/05/2024

11 april 2024 · Leap Therapeutics Announces $40 Million Private Placement · Persbericht

18 maart 2024 · Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

16 januari 2024 · Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium · Persbericht

3 januari 2024 · Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

2 januari 2024 · Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients · Persbericht

11 december 2023 · Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium · Persbericht

13 november 2023 · Leap Therapeutics Reports Third Quarter 2023 Financial Results · Persbericht

5 september 2023 · Leap Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

14 augustus 2023 · Leap Therapeutics Reports Second Quarter 2023 Financial Results · Persbericht

12 juli 2023 · Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients · Persbericht

20 juni 2023 · Leap Therapeutics Announces Reverse Stock Split · Persbericht

25 mei 2023 · Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting · Persbericht

15 mei 2023 · Leap Therapeutics Reports First Quarter 2023 Financial Results · Persbericht

26 april 2023 · Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting · Persbericht

12 april 2023 · Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients · Persbericht

24 maart 2023 · Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results · Persbericht

16 maart 2023 · Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 · Persbericht

6 februari 2023 · Moore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law Firm · Persbericht

23 januari 2023 · SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations · Persbericht

17 januari 2023 · Leap Therapeutics Acquires Flame Biosciences · Persbericht

Mijn selecties